Comparison of a pharmacovigilance screening heuristic with expert clinical consensus for adverse drug reaction signal classification at a Pakistani tertiary care hospital. [PDF]
Pak J Med SciUmer A, Afzal AB, Sethi SM, Arshad A.
europepmc +1 more source
Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes. [PDF]
J Periodontal ResPuzhakkara Chennas A +7 more
europepmc +1 more source
Eisenmenger Syndrome Hidden by Unrepaired Patent Ductus Arteriosus: Diagnosis After Delivery. [PDF]
JACC Case RepMonagle S +4 more
europepmc +1 more source
Hypertension and heart failure: Navigating blood pressure targets and medication titration and tolerance. [PDF]
Clin Med (Lond)Helmy I, Karnib M, Sundaram V.
europepmc +1 more source
Cerebral Sympathetic Nervous System Activation Promotes Intrarenal Renin-Angiotensin System Activity and Salt-Induced Nocturnal Polyuria. [PDF]
Int Neurourol JTsujimura G +13 more
europepmc +1 more source
A Tale of Overlapping Autoimmune Serologies: Diagnosing Hydralazine-Induced Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Related With Isolated Pulmonary Involvement. [PDF]
CureusThapa P, Yadav I, Vinagolu-Baur J.
europepmc +1 more source
A review on the clinical pharmacokinetics of hydralazine
Expert Opinion on Drug Metabolism and Toxicology, 2022 Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure. The current article reviews the clinical pharmacokinetics (PK) of hydralazine, which can be useful for clinicians in optimizing its dose and dosing frequency to ...
Waseem Ashraf, Ammara Zamir
exaly +2 more sources
Related searches:
The bioavailability of orally administered hydralazine was assessed in 4 healthy subjects after separate administration of a single oral or intravenous dose (0.3 mg-kg-1). Comparison of the areas under the serum concentration-time curves showed that 26-55% of the oral dose was available to the systemic circulation as unchanged drug.
openaire +2 more sources